Cargando…
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
Preclinical experimentation revealed that established cancers treated with the immunogenic cell death (ICD) inducer oxaliplatin are sensitized to immune checkpoint inhibitors targeting PD-1. In contrast, no such sensitizing effect is observed when cisplatin, a non-immunogenic cell death inducer is u...
Autores principales: | Liu, Peng, Chen, Jianzhou, Zhao, Liwei, Hollebecque, Antoine, Kepp, Oliver, Zitvogel, Laurence, Kroemer, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235886/ https://www.ncbi.nlm.nih.gov/pubmed/35769948 http://dx.doi.org/10.1080/2162402X.2022.2093518 |
Ejemplares similares
-
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Kroemer, Guido, et al.
Publicado: (2021) -
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012) -
Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020) -
Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis
por: Kepp, Oliver, et al.
Publicado: (2023) -
Tumor-infiltrating lymphocytes for melanoma immunotherapy
por: Kepp, Oliver, et al.
Publicado: (2023)